PL2480541T3 - Krystaliczne hydraty chlorku metylotioniny (błękitu metylenowego) - Google Patents

Krystaliczne hydraty chlorku metylotioniny (błękitu metylenowego)

Info

Publication number
PL2480541T3
PL2480541T3 PL10771516T PL10771516T PL2480541T3 PL 2480541 T3 PL2480541 T3 PL 2480541T3 PL 10771516 T PL10771516 T PL 10771516T PL 10771516 T PL10771516 T PL 10771516T PL 2480541 T3 PL2480541 T3 PL 2480541T3
Authority
PL
Poland
Prior art keywords
hydrates
crystalline
methylene blue
methylthionium chloride
methylthionium
Prior art date
Application number
PL10771516T
Other languages
English (en)
Inventor
Rolf Hilfiker
Timo Rager
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43415329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2480541(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of PL2480541T3 publication Critical patent/PL2480541T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
PL10771516T 2009-09-24 2010-09-23 Krystaliczne hydraty chlorku metylotioniny (błękitu metylenowego) PL2480541T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24539109P 2009-09-24 2009-09-24
PCT/IB2010/002526 WO2011036558A2 (en) 2009-09-24 2010-09-23 Crystalline methylthionium chloride (methylene blue) hydrates
EP10771516.1A EP2480541B1 (en) 2009-09-24 2010-09-23 Crystalline methylthionium chloride (methylene blue) hydrates

Publications (1)

Publication Number Publication Date
PL2480541T3 true PL2480541T3 (pl) 2016-03-31

Family

ID=43415329

Family Applications (4)

Application Number Title Priority Date Filing Date
PL20203173.8T PL3792254T3 (pl) 2009-09-24 2010-09-23 Krystaliczne hydraty chlorku metylotioniny
PL18170358T PL3378856T3 (pl) 2009-09-24 2010-09-23 Krystaliczne hydraty chlorku metylotioniny
PL15176967T PL2963024T3 (pl) 2009-09-24 2010-09-23 Krystaliczne hydraty chlorku metylotioniny - część 2
PL10771516T PL2480541T3 (pl) 2009-09-24 2010-09-23 Krystaliczne hydraty chlorku metylotioniny (błękitu metylenowego)

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL20203173.8T PL3792254T3 (pl) 2009-09-24 2010-09-23 Krystaliczne hydraty chlorku metylotioniny
PL18170358T PL3378856T3 (pl) 2009-09-24 2010-09-23 Krystaliczne hydraty chlorku metylotioniny
PL15176967T PL2963024T3 (pl) 2009-09-24 2010-09-23 Krystaliczne hydraty chlorku metylotioniny - część 2

Country Status (19)

Country Link
US (1) US8765742B2 (pl)
EP (4) EP3378856B1 (pl)
JP (1) JP5806217B2 (pl)
KR (3) KR20170061177A (pl)
CN (2) CN102666511B (pl)
AU (1) AU2010299571B2 (pl)
BR (4) BR122019022631B8 (pl)
CA (4) CA2773305C (pl)
DK (4) DK2963024T3 (pl)
ES (4) ES2557318T3 (pl)
FI (1) FI3792254T3 (pl)
HR (3) HRP20181567T2 (pl)
MX (3) MX355627B (pl)
MY (1) MY159782A (pl)
PL (4) PL3792254T3 (pl)
PT (4) PT2480541E (pl)
SG (1) SG10201408584UA (pl)
SI (4) SI3792254T1 (pl)
WO (1) WO2011036558A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2011036561A2 (en) * 2009-09-24 2011-03-31 Wis Ta Laboratories Ltd. Process
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10765755B1 (en) 2013-11-20 2020-09-08 University Of South Florida Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
WO2024063700A1 (en) 2022-09-21 2024-03-28 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases
GB202500018D0 (en) 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
DK2004155T3 (en) 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
CN104119294B (zh) * 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
US8227459B2 (en) * 2007-04-03 2012-07-24 Prosetta Antiviral Inc. Diamino-phenothiazinyl derivatives as antiviral treatments
US7603854B2 (en) 2007-04-10 2009-10-20 Illinois Tool Works Inc. Pneumatically self-regulating valve

Also Published As

Publication number Publication date
ES2689029T3 (es) 2018-11-08
HRP20210086T1 (hr) 2021-03-05
HRP20181567T2 (hr) 2022-09-30
CA3004822A1 (en) 2011-03-31
CA2773305C (en) 2018-07-03
HK1167653A1 (zh) 2012-12-07
US8765742B2 (en) 2014-07-01
CA3141737A1 (en) 2011-03-31
JP2013505925A (ja) 2013-02-21
PT2480541E (pt) 2016-01-26
SI2963024T1 (sl) 2018-10-30
CA3141737C (en) 2023-10-03
PT3792254T (pt) 2023-10-19
EP3792254A1 (en) 2021-03-17
FI3792254T3 (fi) 2023-09-22
CA3004822C (en) 2020-07-21
WO2011036558A3 (en) 2011-11-24
BR122019022631B1 (pt) 2021-03-16
BR122019022628B8 (pt) 2021-07-27
HRP20231201T1 (hr) 2024-01-19
CN102666511A (zh) 2012-09-12
EP3378856A2 (en) 2018-09-26
EP2963024A3 (en) 2016-02-17
CN105061358A (zh) 2015-11-18
ES2557318T3 (es) 2016-01-25
ES2960761T3 (es) 2024-03-06
DK3378856T3 (da) 2020-12-21
BR122019022631B8 (pt) 2021-07-27
EP2480541B1 (en) 2015-11-04
JP5806217B2 (ja) 2015-11-10
WO2011036558A9 (en) 2011-08-04
WO2011036558A2 (en) 2011-03-31
KR20120099409A (ko) 2012-09-10
PT3378856T (pt) 2021-02-02
BR122019022628B1 (pt) 2021-03-16
US20120238556A1 (en) 2012-09-20
HK1213897A1 (en) 2016-07-15
CA3077911C (en) 2022-03-01
SI3378856T1 (sl) 2021-03-31
SG10201408584UA (en) 2015-02-27
MX355627B (es) 2018-04-25
MX2012003083A (es) 2012-04-30
BR122019022612B1 (pt) 2021-03-09
AU2010299571B2 (en) 2014-07-31
EP3378856B1 (en) 2020-12-02
SI2480541T1 (sl) 2016-02-29
ES2847003T3 (es) 2021-07-30
BR122019022612B8 (pt) 2021-07-27
KR20170061177A (ko) 2017-06-02
HRP20181567T1 (hr) 2018-11-30
DK3792254T3 (da) 2023-09-25
SI3792254T1 (sl) 2023-11-30
EP2480541A2 (en) 2012-08-01
DK2480541T3 (en) 2016-02-01
MX381636B (es) 2025-03-13
BR112012006638B1 (pt) 2020-05-26
CA3077911A1 (en) 2011-03-31
MY159782A (en) 2017-01-31
CN102666511B (zh) 2015-09-16
PT2963024T (pt) 2018-10-16
CA2773305A1 (en) 2011-03-31
EP3792254B1 (en) 2023-07-26
BR112012006638A2 (pt) 2016-05-03
EP3378856A3 (en) 2018-11-07
PL3378856T3 (pl) 2021-05-31
PL3792254T3 (pl) 2024-02-12
AU2010299571A1 (en) 2012-04-12
DK2963024T3 (en) 2018-10-08
EP2963024A2 (en) 2016-01-06
EP2963024B1 (en) 2018-07-18
KR20180094126A (ko) 2018-08-22
PL2963024T3 (pl) 2019-02-28

Similar Documents

Publication Publication Date Title
SI2480541T1 (sl) Kristalinični hidrati metiltioninijevega klorida (metilen modrega)
GB0906472D0 (en) New compounds
GB0906470D0 (en) New compounds
EP2483254A4 (en) NEW COMPOUNDS
GB0905955D0 (en) Novel compounds
GB0900388D0 (en) New compounds
GB0903493D0 (en) New compounds
EP2512242A4 (en) NEW COMPOUNDS
AU2014253566B2 (en) Crystalline methylthionium chloride (methylene blue) hydrates
GB0910009D0 (en) Novel compounds
GB0910667D0 (en) Novel compounds
GB0907825D0 (en) Novel compound
GB0903482D0 (en) New compounds
GB0907204D0 (en) Novel compounds
GB0909303D0 (en) Novel compounds
GB0906288D0 (en) Novel compounds
GB0910673D0 (en) Novel compounds
GB0902727D0 (en) Novel compounds
GB0907121D0 (en) Novel compounds
GB0907114D0 (en) Novel compounds
GB0907137D0 (en) Novel compounds
GB0907113D0 (en) Novel compounds
GB0901246D0 (en) Novel compounds
GB0907118D0 (en) Novel compounds
GB0907106D0 (en) Novel compounds